When it comes to durability, Hybrid ablation has demonstrated to be effective in Afib treatment.
​
The CEASE-AF randomized-controlled trial highlights the long-term effectiveness of Hybrid ablation, showing sustained results over 24 months and a ~33% absolute increase in freedom from atrial arrhythmias* for patients with long-standing persistent Afib.​

Discover more about the CEASE-AF Trial: <a href="https://okt.to/PxwTtA&quot; target="_blank">https://okt.to/PxwTtA</a&gt;

<a href='https://www.linkedin.com/feed/hashtag/?keywords=CardiacSurgery&highligh…; target='_blank'>#CardiacSurgery</a> <a href='https://www.linkedin.com/feed/hashtag/?keywords=Epeeps&highlightedUpdat…; target='_blank'>#Epeeps</a>​​

Dr. <a href="https://twitter.com/Pouya_HemmatiMD&quot; target="_blank">@Pouya_HemmatiMD</a> and <a href="https://twitter.com/BaptistHealthAR&quot; target="_blank">@BaptistHealthAR</a> kick off the year with their 1st EPi-Sense ST™ case! This innovative device offers enhanced control for epicardial <a href="https://twitter.com/hashtag/Afib?src=hashtag_click&quot; target="_blank">#Afib</a> ablation, bringing new options to LSPAF patients.
 
Learn more: <a href="https://t.co/W8Q5KIEFZ1&quot; target="_blank">https://t.co/W8Q5KIEFZ1</a&gt;
<a href="https://twitter.com/hashtag/HybridAFTherapy?src=hashtag_click&quot; target="_blank">#HybridAFTherapy</a>

Dr. Pouya Hemmati and the team at Baptist Health Medical Center Little Rock are starting the new year strong with their first case using the EPi-Sense ST™ device!

This innovative device enhances deflection and control for epicardial Afib ablation, offering a new treatment option for patients with long-standing persistent Afib.

Learn more about EPi-Sense ST: <a href="https://okt.to/QmuBhY&quot; target="_blank">https://okt.to/QmuBhY</a&gt; <a href='https://www.linkedin.com/feed/hashtag/?keywords=HybridAFTherapy&highlig…; target='_blank'>#HybridAFTherapy</a> <a href='https://www.linkedin.com/feed/hashtag/?keywords=Afib&highlightedUpdateU…; target='_blank'>#Afib</a>

2024 was an incredible year at AtriCure! From global growth and groundbreaking innovations to key clinical milestones and impactful community outreach—there’s much to share. Watch as <a href="https://twitter.com/AtriCureCEO&quot; target="_blank">@AtriCureCEO</a> Mike Carrel recaps it all and looks ahead to what 2025 has in store.

<a href="https://twitter.com/hashtag/Innovaton?src=hashtag_click&quot; target="_blank">#Innovaton</a>… <a href="https://t.co/HWtkJB175N&quot; target="_blank">https://t.co/HWtkJB175N</a&gt;

2024 was an incredible year at AtriCure! From global growth and groundbreaking innovations to key clinical milestones and impactful community outreach—there’s much to share. Watch as CEO Michael Carrel recaps it all and looks ahead to what 2025 has in store.

<a href='https://www.linkedin.com/feed/hashtag/?keywords=Innovaton&highlightedUp…; target='_blank'>#Innovaton</a> <a href='https://www.linkedin.com/feed/hashtag/?keywords=ClinicalScience&highlig…; target='_blank'>#ClinicalScience</a>

Taking post-op pain management to the MAX. With a 50% reduction in freeze time, the cryoSPHERE® MAX device offers a faster solution for post-op pain management.​​
​
Learn more about the latest innovation: <a href="https://t.co/L1KYPmEfOr&quot; target="_blank">https://t.co/L1KYPmEfOr</a&gt;
<a href="https://twitter.com/hashtag/cryoNB?src=hashtag_click&quot; target="_blank">#cryoNB</a>

Taking post-op pain management to the MAX. With a 50% reduction in freeze time, the cryoSPHERE® MAX device offers a faster solution for post-op pain management.​​
​
Learn more about the latest innovation: <a href="https://okt.to/GfsY5y&quot; target="_blank">https://okt.to/GfsY5y</a&gt;
<a href='https://www.linkedin.com/feed/hashtag/?keywords=cryoNB&highlightedUpdat…; target='_blank'>#cryoNB</a>​

Tune in as EP Dr. Chad Brodt shares insights on the ongoing HEAL-IST Trial for patients with symptomatic Inappropriate Sinus Tachycardia (IST). Discover who may qualify and learn more about the trial by visiting <a href="https://t.co/gdla3fPxty.&quot; target="_blank">https://t.co/gdla3fPxty.</a&gt;​

<a href="https://twitter.com/hashtag/Epeeps?src=hashtag_click&quot; target="_blank">#Epeeps</a> <a href="https://twitter.com/hashtag/ClinicalTrial?src=hashtag_click&quot; target="_blank">#ClinicalTrial</a> <a href="https://twitter.com/hashtag/CardioTwitter?src=hashtag_click&quot; target="_blank">#CardioTwitter</a>

Tune in as Electrophysiologist Dr. Chad Brodt shares insights on the ongoing HEAL-IST Trial for patients with symptomatic Inappropriate Sinus Tachycardia (IST). Discover who may qualify and learn more about the trial by visiting heal-ist.com.​

<a href='https://www.linkedin.com/feed/hashtag/?keywords=IST&highlightedUpdateUr…; target='_blank'>#IST</a> <a href='https://www.linkedin.com/feed/hashtag/?keywords=InnapropriateSinusTachy…; target='_blank'>#InnapropriateSinusTachycardia</a> <a href='https://www.linkedin.com/feed/hashtag/?keywords=ClinicalTrial&highlight…; target='_blank'>#ClinicalTrial</a> ​

Dr. David Kress, a pioneer in Hybrid AF™ Therapy with Dr. Jasbir Sra, retires after 300+ hybrid cases. Dr. Kress’ impact on patient care have left an indelible mark on the arrhythmia community.

Discover the therapy bringing long-lasting relief to LSPAF patients:… <a href="https://t.co/7rIljszhhj&quot; target="_blank">https://t.co/7rIljszhhj</a&gt;